骨髓中CDKN1C阳性表达在MDS和AML患者中检测的临床意义

目的 探讨骨髓中CDKN1C阳性表达在骨髓增生异常综合征(MDS)和继发性急性髓系白血病(AML)患者中检测的临床意义。方法 选取125例MDS/AML患者作为研究对象,同时选取20例健康人群作为健康对照组,分析MDS/AML患者骨髓CD34⁺细胞中CDKN1C的mRNA和蛋白表达水平,比较不同CDKN1C表达水平的MDS患者生存率,采用Cox回归分析MDS和AML患者生存率影响因素,并分析治疗方法对不同CDKN1C表达水平的MDS患者生存率的影响。结果 MDS/AML患者骨髓CD34⁺细胞中CDKN1C mRNA和蛋白表达水平显著高于健康对照组,且与BM(Bone marrow)比例呈正相关(r=0.423,P=0.012);CDKN1C高表达组患者的生存率显著低于CDKN1C低表达组和CDKN1C中表达组(P＜0.05);Cox回归分析结果显示高龄、高BM比例、细胞遗传学风险差以及CDKN1C阳性显著影响MDS/AML患者生存率(P＜0.05);MDS/AML化疗的CDKN1C阳性表达组患者生存率显著低于CDKN1C阴性组患者(P＜0.05),MDS/AML化疗后造血干细胞移植(AlloSCT)的CDKN1C阳性组患者生存率显著低于CDKN1C阴性组患者(P＜0.05)。结论 MDS/AML患者骨髓中CDKN1C的表达显著增高,CDKN1C阳性表达显著影响化疗MDS/AML患者的预后生存。

Clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia

Objective The aim of this study was to investigate the clinical significance of CDKN1C positive expression in bone marrow in patients with myelodysplastic syndrome and secondary acute myeloid leukemia.Methods 125 patients with MDS/AML were selected as the research subjects,and selected 20 healthy subjects as a healthy control group.The mRNA and protein expression levels of CDKN1C in CD34⁺ cells of MDS/AML patients were analyzed.The expression levels of CDKN1C were compared with those of MDS patients.The survival rate of patients with MDS and AML was analyzed by Cox regression analysis.The survival rate of MDS patients with different expression levels of CDKN1C was also analyzed.Results The expression of CDKN1C at levels of mRNA and protein in bone marrow CD34⁺ cells of MDS/AML patients were significantly higher than those in healthy controls(P＜0.05).There has a positive correction with BM(P＜0.05).The survival rate of CDKN1C high expression group was significantly lower than that in the low and mediate CDKN1C expression groups(P＜0.05).The results of Cox regression analysis showed that age,high BM count,cytogenetic difference and the positive expression of CDKN1C significantly affected the survival rate of patients with MDS/AML(P＜ 0.05);The survival rate of MDS/AML chemotherapy in the CDKN1C positive group was significantly lower than that of CDKN1C negative expression group(P＜0.05).The survival rate of MDS/AML after chemotherapy AlloSCT CDKN1C positive expression group was significantly lower than that of CDKN1C negative expression group(P＜0.05).Conclusion The expression of CDKN1C in bone marrow of MDS/AML patients was significantly increased,and the positive expression of CDKN1C significantly increased,and the positive expression of CDKN1C significantly affected the survival rate of MDS/AML patients.